Faron Pharmaceuticals Appoints Dr. Petri Bono as New Chief Medical Officer

August 06, 2024 07:48 PM AEST | By Team Kalkine Media

Google News:

Faron Pharmaceuticals Appoints Dr. Petri Bono as New Chief Medical Officer — Image source: © Andreyyalansky19 | Megapixl.com

Recent News

Zeus Resources Advances Casablanca Acquisition in Morocco | ASX 200

IDX:ANTM Expands EV Battery Ecosystem with New Industrial Push in ASEA...

Celebrating the Future of Accounting - One Student at a Time

ASX 200 Dips as Market Swings on Trade Uncertainty; Utilities Cushion...

Faron Pharmaceuticals Ltd. (AIM:FARN), a clinical-stage biopharmaceutical company focused on pioneering CLEVER-1 receptor-targeting approaches to enhance anti-tumor immunity in treatment-resistant cancers, has announced the appointment of Dr. Petri Bono (M.D., Ph.D.) as its new Chief Medical Officer (CMO), effective from 15 August 2024.

Dr. Bono's Extensive Background

Dr. Bono brings a wealth of experience to Faron Pharmaceuticals, having previously served as Chief Medical Officer and a member of the executive team at Terveystalo, Finland's largest private healthcare service provider. His prior roles include Chief Medical Officer at Helsinki University Hospital, where he also held positions as Associate Professor of Cancer Biology and Director of the Comprehensive Cancer Center. Dr. Bono's leadership in oncology includes participation in numerous trials from Phase 1 to 3, particularly in immuno-oncology, and he has contributed 102 peer-reviewed papers to prestigious journals such as the New England Journal of Medicine, Lancet Oncology, JAMA, and Cancer Cell.

Strategic Fit with Faron's Mission

Dr. Bono’s extensive background in molecular and immunological oncology aligns seamlessly with Faron Pharmaceuticals' mission. His experience in translational and clinical studies of targeted therapies and immunology positions him uniquely to advance Faron's immuno-oncology programs. Faron is dedicated to developing novel myeloid cell-targeting immunotherapies, with the aim of expanding the reach of immunotherapy to broader patient populations, particularly within the solid tumor space.

Anticipated Impact

Faron Pharmaceuticals anticipates that Dr. Bono's expertise will significantly bolster its immuno-oncology program. His leadership is expected to drive forward the company's innovative approaches in tackling cancers, particularly those resistant to current treatments. With his proven track record in oncology research and clinical trials, Dr. Bono is poised to make a substantial impact on the company's ongoing and future therapeutic developments.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.